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ABSTRACT 
 
Multiple sclerosis (MS) is the leading cause of non-traumatic neurological disability in young 
adults. Although the cause of the disease is unknown, several genetic and environmental risk 
factors have been identified. By studying these risk factors in experimental systems we can 
learn more about the biological events that precede overt disease and then use this knowledge 
in the development of better and safer MS treatments. 
The aim of the work presented in this thesis is to shed light on one of the established genetic 
risk factors, the single nucleotide polymorphism (SNP) rs17066096. Since this SNP is 
positioned close to the gene IL22RA2, we hypothesize that IL22RA2 mediates the effect on 
MS susceptibility. The gene product of IL22RA2 is interleukin-22 binding protein (IL-22BP), 
a soluble IL-22 antagonist. Consequently, in study I-IV below, we focus on the role of the IL-
22-system in MS and experimental inflammation models. 
In study I we reveal the role of IL-22BP in MS animal model experimental autoimmune 
encephalomyelitis (EAE). Il22ra2-deleted mice have less severe paralysis, immune cell 
infiltration, and demyelination compared to wild type mice.  
In study II we further investigate the biology of IL-22BP in inflammation. We use the mouse 
strain from study I, but now in two skin inflammation models: contact hypersensitivity and an 
imiquimod-induced psoriasis model. In contrast to EAE, the Il22ra2-deleted mice have more 
severe disease in both skin inflammation models. 
In study III we show that the risk genotype of rs17066096 is associated with higher 
expression of IL22RA2 in monocyte-derived dendritic cells from healthy blood donors and 
that MS patients with more lesions on magnetic resonance imaging have higher cerebrospinal 
fluid levels of IL-22BP. Using an inducible Il22ra2-knockdown rat strain we show that a 
relatively modest decrease in Il22ra2 expression is enough to make the rats resistant to EAE. 
Similarly, heterozygous deletion of Il22ra2 in mice is sufficient to achieve a protective effect. 
Furthermore, we establish that the protective effect in Il22ra2-deleted mice is dependent on 
the presence of IL-22. 
In study IV we investigate the effect of IL-22 signaling on the initiation of an adaptive 
immune response. Using the rat strain from study III, we show that knockdown of Il22ra2 
expression just prior to immunization causes a reduction in lymphocyte expansion, 
preferentially affecting B cells, as well as a reduction in antigen specific effector functions in 
B cells and Th1 cells. 
In conclusion, we present data in support of a disease-promoting role for IL-22BP in 
neuroinflammation in three species. We show that the effect is dependent on IL-22, which 
consequently has a therapeutic potential. 
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1 INTRODUCTION 
 
The work presented in this thesis stems from previous studies by our group that gave rise to 
the following question:  How does the interleukin-22 binding protein (IL-22BP) influence 
multiple sclerosis (MS) and its experimental models? The following section will provide 
background before proceeding with a discussion of the results. Topics covered will be: the 
biology and genetic variation of the immune system, interleukin-22 (IL-22) physiology and 
pathophysiology, neuroinflammation with focus on MS, and other inflammation models. 
 
1.1 NEUROINFLAMMATION 
1.1.1 Neuroimmunology  
Clinical neuroimmunology encompasses the study of immune mediated neurological 
disorders, which are set apart from other inflammatory disorders by the following three 
characteristics: i) immune privilege, ii) limited tissue regeneration and iii) limited access by 
therapeutic agents. 
1.1.1.1 Immune privilege 
The concept of immune privilege was first described after experiments conducted by Peter 
Medawar in the 1940’s1. It is based on the observation that tissue grafts placed in certain 
tissue environments fail to elicit an immune response and are not rejected. Organs that are 
considered immune privileged include the brain, eyes, testes and uterus. In the brain, the 
features that classically are proposed to constrain the activity of the immune system include:  
- The blood-brain barrier (BBB) that keeps immune cells outside the CNS 
- Limited lymphatic drainage 
- Few antigen-presenting cells in the brain parenchyma 
- Limited expression of major histocompatibility complex (MHC) molecules.  
The BBB restricts the passage of cells, antibodies and other molecules from the circulating 
blood to the extracellular space in the CNS. It is formed by endothelial cells with tight 
junctions, even around the capillaries2,3. Apart from these endothelial cells, the BBB also 
consists of an endothelial basement membrane, scattered contractile cells called pericytes, a 
parenchymal basement membrane and finally a layer of astrocytic foot processes also known 
as the glia limitans. Many gases and lipid soluble molecules can diffuse freely across the 
BBB but other molecules essential for neural function – e.g. glucose and amino acids - are 
taken up by selective transport mechanisms4,5. 
The BBB is not an absolute immune cell barrier. Experiments in rodents show that 
encephalitogenic T cells transferred to the peripheral circulation of healthy animals do cross 
the BBB and enter the CNS where they cause neuroinflammation6. Furthermore, immune cell 
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surveillance has been shown to occur in the healthy CNS7,8. Parts of the intracerebral blood 
vessels, such as the circumventricular organs and the choroid plexus9,10, more readily allow 
the passage of immune cells. 
Lymphatic drainage from the cerebrospinal fluid (CSF) to the peripheral circulation has 
recently been well characterized in mice using modern microscopy technology11,12. 
Lymphatic vessels line the dural sinuses and drain to the deep cervical lymph nodes. These 
vessels give the immune cells in the CNS a route to travel to deep cervical lymph nodes, 
where an immune response can be elicited. It may be so that CNS antigens rather induce 
tolerance under these circumstances13. This conclusion recently became contested, however14. 
Interestingly, myelin-specific T cells are not only found in MS patients, but also in healthy 
individuals and naïve mice, in which case they do not cause disease15,16. 
The brain parenchyma is largely devoid of efficient antigen-presenting cells in the steady 
state. However, these cells do exist in the meninges and in association with blood vessels, 
where they are thought to activate T cells at initiation of disease17–20. 
1.1.1.2 CNS response to injury 
Any form of significant injury to the CNS will result in a coordinated response from local 
cells, i.e. neurons and glia, and in most instances also from infiltrating immune cells21,22. The 
immune cells have a critical role in the defense against microbial pathogens, but also in 
clearing up debris that would otherwise interfere with the normal functions of the nervous 
tissue23–25. Fine-tuning this inflammatory immune response is very important in the CNS - 
perhaps more so than in other organs, because excessive activation will lead to damage that is 
likely to be irreversible, due to the very limited regenerative potential of neurons in the CNS. 
However, there are reports showing reversible axon damage in MS and EAE26. Primarily 
microglia, but to some extent also astrocytes, act as sensors of damage and recruiters of 
leukocytes to the CNS27–30. Astrocytes also respond in a characteristic way to limit the 
collateral damage to neighboring parenchyma by proliferating to enclose the lesion in a 
process called astrogliosis, similar to scar formation. This phenomenon was recognized early 
by histopathological studies and was for a long time viewed simply as a harmful response 
that limited synapse sprouting and axon growth. However, a large number of experimental in 
vivo studies have now shown that astrogliosis in many cases improves outcomes through 
what is interpreted as promotion of wound closure, neuroprotection, restoration of the BBB 
and resolution of inflammation30,31. 
1.1.2 MS - introduction 
MS is a chronic inflammatory disease of the CNS and is the second most common cause of 
neurological disability in the young, after traumatic injuries32. It is typically characterized by 
recurring bouts of motor and/or sensory deficits, which are manifestations of immunological 
attacks on the myelin sheaths that surround axons in the CNS. If the axons remain intact after 
inflammation has resolved, the symptoms will remit after remyelination has taken place 
(Figure 1). Subclinical attacks on the CNS take place even before the initial presentation of 
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neurological symptoms. These can be demonstrated radiologically by magnetic resonance 
imaging (MRI). It is currently discussed whether radiologically isolated syndrome (RIS) is a 
useful term for this situation, which in extension would encourage a more active management 
of these patients33. The first clinical presentation consistent with MS is called clinically 
isolated syndrome (CIS), assuming that the diagnostic criteria for MS are not already 
fulfilled. Relapsing remitting MS (RRMS) is the classical disease phenotype, characterized 
by bouts of neurological symptoms followed by remissions that may be complete or 
incomplete. After approximately 10-15 years most RRMS have converted to secondary 
progressive MS (SPMS), characterized by a steady decline of neurological functions with or 
without superimposed relapses. However, this may no longer be the case with the more 
efficacious treatments that have become available in the last few years. Furthermore, 
approximately 5-10% of MS patients present with progressive disease directly from the 
outset, called primary progressive MS (not shown in Figure 1.). Brain atrophy can be 
detected early but accelerates as disease advances.  
              
 
 
Figure 1. Clinical phenotypes of MS.  
 
The prevalence of MS in Scandinavia is particularly high, at approximately 1-2 per 100034,35. 
The worldwide prevalence of MS is much lower but it is difficult to arrive at an accurate 
number. Like most autoimmune diseases, there is a gender bias. In the case of MS, there are 
approximately 2-3 affected females per male. The explanation could be multi-factorial but a 
strong case has been built implicating sex hormones36,37. Females generally have higher 
antibody responses than males, a fact that is reflected by the strikingly higher incidence in 
females of the antibody-driven autoimmune disease systemic lupus erythematosus (SLE). 
During pregnancy there is a shift away from Th1 type immunity, further favoring Th2 and 
antibody responses, presumably for the purpose of promoting tolerance to the fetus38.  This 
general shift in the immune system is believed to underlie the observed pregnancy-related 
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increase in relapse frequency for antibody-driven autoimmune disease (e.g. SLE and systemic 
sclerosis) and a decrease in relapse frequency for Th1/Th17-driven autoimmune diseases (e.g. 
MS and rheumatoid arthritis)38, as well as the phenomenon of postpartum relapses39. 
Additionally, for MS the gender bias has increased over time, which may be an effect of 
changes in sunlight exposure and/or vitamin D levels40,41.  
1.1.3 MS - genes and environment 
1.1.3.1 Genetic risk factors 
The cause of MS is not known but it is believed that the disease is initiated in individuals for 
which the combination of genetic predisposition and environmental exposures reaches a 
threshold42. According to this model, there can be many different causes of MS. A simplified 
example: in one MS patient, genetic risk factors 1 and 2 in combination with environmental 
risk factor A was sufficient to reach the threshold of disease initiation and in another MS 
patient, genetic risk factor 3 in combination with environmental risk factors B and C was 
sufficient to cause the disease. A large amount of knowledge has accumulated about the 
genetic and environmental risk factors that influence susceptibility but those that influence 
severity and subphenotype are much less understood43–48. This, in turn is a consequence of a 
lack of good methods to assess severity, subphenotype and disease progression.  
Familial clustering of MS was recognized early and the recurrence risk for first-degree 
relatives has previously been reported at approximately 3-5 %, 30-50 times the risk in the 
general population49–52. However, more recent data, without some of the bias inherent to the 
previous studies, estimate the recurrence risk at approximately 7 times the population risk for 
first-degree relatives53. From this observation alone, one cannot distinguish the relative 
importance of shared genetics or shared environment. The concordance rate for monozygotic 
twins has been reported at approximately 30 %, which is comparable to many other 
autoimmune diseases, e.g. rheumatoid arthritis and psoriasis49–51,54,55. Heritability, classically 
defined by comparing concordance rate in monozygotic and dizygotic twins, has been 
difficult to estimate with precision for MS, mainly due to relatively low prevalence56. 
Moreover, twin studies are generally problematic owing to small study groups and inability to 
distinguish genetic causes from intrauterine environmental causes. Stronger evidence for a 
genetic contribution comes from studies of adoptees and half-siblings. The susceptibility for 
first-degree non-biological relatives living with a person with MS is the same as for the 
general population57. The risk for siblings is approximately doubled compared to half-
siblings58.  
Once a significant genetic contribution to disease susceptibility has been demonstrated the 
next step is to identify the genes, or more specifically the genomic sequence variants that 
mediate these effects. Disease associated variants can be classified as those that directly cause 
the disease, which result in Mendelian inheritance patterns, or those that just modulate a 
person’s resistance to environmental disease triggers. The first type of variant is by necessity 
rare. Any de novo germline mutation having a large impact on MS susceptibility would 
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quickly have been lost because the carriers would not have been able to successfully produce 
and care for offspring. Consequently, it is perhaps not surprising that the identified genetic 
risk factors individually all have relatively small effects on MS susceptibility.  
Early population based studies focused on candidate genes that were chosen based on the 
hypothesis of T cell mediated autoimmune demyelination. The first identified genetic risk 
factor mapped to MHC class I, which was later extended to class II as well59,60. Due to strong 
linkage disequilibrium (LD) in this region it has, to this day, not been possible to isolate the 
primary allele for this association. A haplotype including the DRB1*1501 allele is by far the 
most important genetic risk factor identified61,62. Interestingly, the MHC also includes the 
genes for the central driver of inflammation tumor necrosis factor (TNF) and MS autoantigen 
candidate myelin oligodendrocyte glycoprotein (MOG), none of which have however shown 
convincing associations to MS that are independent of MHC class II. The HLA molecules in 
the MHC region present antigens to the T cell receptor (TCR). However, studies of germline 
sequence variation in the TCR α and β chain genes have given little support for the 
involvement of the TCR in genetic predisposition to MS63. Similarly studies focusing on 
immunoglobulins have yielded inconsistent observations.  
Association studies are hypothesis-driven population-based studies of candidate genes. An 
alternative approach is linkage studies, which are performed on MS families and identifies 
susceptibility loci in an unbiased manner. However, with the advent of high throughput SNP-
genotyping, association studies are now performed that are essentially hypothesis-free. The 
genotyped SNPs are chosen based on strong LD with neighboring SNPs, thus serving as 
markers for haplotype blocks64. In these studies a few hundred thousand so called tagging-
SNPs are genotyped from which one can, with reasonable certainty, assume the alleles of 
neighboring untyped SNPs. One distinct difference between these two approaches is that 
association studies will only be able to identify common variants. Linkage studies are 
required to identify rare variants. Now that several very large genome wide associations 
studies have been finalized it has become clear that the identified risk variants, now more 
than a hundred, all have small effects on disease susceptibility and the combined effects of 
these do not seem to correspond to the observed heritability44,45,65. Two hypotheses about the 
genetic determinants of MS susceptibility have been discussed i) common variants with small 
effects, which are the ones identified by performing association studies and ii) rare variants 
with large effects, which can only be identified by performing linkage studies. The later 
scenario, sometimes called the mutation-selection hypothesis, proposes that much 
susceptibility is due to variants of recent origin. These would exhibit great allelic 
heterogeneity, but perhaps not as pronounced locus heterogeneity. For comparison, the severe 
but fairly common Mendelian disease cystic fibrosis is due to single mutations in one gene, 
CFTR, but the number of known mutations add up to more than a thousand. These would not 
be identified by association studies. Resequencing of candidate regions, or perhaps of entire 
genomes, would be needed. Other hypotheses for the ”missing heritability” are epistatic 
effects, i.e. the effect of a risk factor may be much larger in the presence of another risk 
factor, or epigenetic effects. 
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1.1.3.2 Molecular characterization of genetic risk factors 
To date, more than a hundred SNPs have been associated with MS susceptibility and the 
number is expected to increase as further studies are published. Molecular characterization of 
these genetic risk factors has made relatively slow progress, however. Examples for which 
significant progress has been made include: the IL-7 receptor alpha chain (IL7R)66, TNF 
superfamily 1A (TNFRSF1A)67, the IL-2-receptor alpha chain (IL2RA)68,69, and Tyrosine 
kinase 2 (TYK2)70. 
IL7R 
The IL-7 receptor is a dimer of the IL-7 receptor alpha chain and the common gamma chain. 
IL-7 is important for differentiation and homeostasis of all lymphoid cells. Exaggerated IL-7 
signaling has been shown to promote autoimmunity71–74.An alternatively spliced, soluble 
form of the IL-7 receptor exists, which is produced by skipping exon 6. The risk-allele of the 
MS-associated SNP rs6897932, located in exon 6 of IL7R, results in a higher proportion of 
the soluble form of the IL-7 receptor being produced66. A proposed mechanism for the effect 
of an increase of the soluble IL-7 receptor on MS-risk is by its competition with the 
membrane bound receptor for circulating IL-7, thus leading to overall lower consumption of 
the cytokine. This in turn, increases concentrations of circulating IL-7, which has the 
potential to promote autoimmune processes.  
TNFSF1A 
TNFRSF1A encodes TNF receptor 1. The MS-risk allele of the intronic SNP rs1800693 leads 
to a skipped exon during splicing, which produces a soluble form of the receptor that blocks 
TNF-signaling67. The SNP is not associated with any of the other autoimmune diseases, like 
rheumatoid arthritis, psoriasis, Crohn’s disease. This is mirrored by the treatment response to 
TNF-blockade, an established treatment for these diseases, but that exacerbates MS75. 
IL2RA 
The IL-2-receptor alpha chain, also known as CD25, forms the high-affinity IL-2 receptor 
when incorporated with IL-2 receptor beta and the common gamma chain76. The MS-
associated allele of the intronic rs2104286 increases cell surface expression of CD25, which 
results in more production of GM-CSF upon IL-2 stimulation68,69. 
TYK2 
TYK2 is associated with the cytoplasmic tail of many cytokine receptors and is involved in 
signal transduction upon activation. MS-associated SNP rs3456443 causes a missense 
mutation in exon 21 of the gene TYK2 that results in a change from a proline to an alanine. It 
does not affect TYK2 expression levels but does change activity of the gene70. The protective 
allele reduces TYK2 activity in T cells and results in a shift towards Th2 cytokine production. 
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1.1.3.3 Environmental risk factors 
Environmental risk factors are more difficult to identify without bias. The most well 
established factors that increase the risk of MS on a population level are: smoking, late 
Epstein-Barr virus (EBV) infection, obesity, low vitamin D levels, and a striking geographic 
distribution that may be caused by variations in exposure to sunlight42,77–82. Although a large 
body of data exists on the matter, the underlying pathogenic mechanisms are largely 
unresolved. 
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Locus                                       Gene(s) p-value Odds ratio 
1p36.32 MMEL1 1.3 x 10-26 1.14 
1p22.3 DDAH1 4.4 x 10-9 1.09 
1p22.1 EVI5, RPL5 1.4 x 10-26 1.19 
1p21.2 VCAM1 1.9 x 10-16 1.10 
1p13.1 CD58 5.0 x 10-42 1.29 
1q31.2 RGS1 4.8 x 10-20 1.15 
1q32.1 C1orf106 4.0 x 10-19 1.13 
2p13.3 PLEK 1.2 x 10-13 1.10 
2q37.1 SP140 4.2 x 10-23 1.16 
3p24.1 EOMES 1.5 x 10-15 1.10 
3q13.33 CD86, TIMMDC1, IQCB1 1.2 x 10-24 1.13 
3q25.33 IL12A 1.1 x 10-18 1.11 
5p13.2 IL7RA 4.3 x 10-17 1.12 
5p13.1 PTGER4 6.9 x 10-16 1.21 
5q31.3 NDFIP1 3.6 x 10-9 1.07 
5q35.3 RGS14 4.4 x 10-18 1.12 
6p21.32 HLA-DRB1 
1.0 x 10-
225 
2.75 
6q15 BACH2 1.5 x 10-15 1.14 
6q23.3 OLIG3, TNFAIP3, IL22RA2, AHI1 1.6 x 10-23 1.14 
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6q25.3 TAGAP 8.0 x 10-21 1.12 
8q24.21 MYC, MIR1204, MIR1205, PVT1, MIR1208, MIR3686 4.3 x 10-16 1.12 
10p15.1 IL2RA 2.3 x 10-47 1.22 
10q22.3 ZMIZ1 2.5 x 10-15 1.10 
10q23.33 HHEX 4.3 x 10-17 1.11 
11q12.2 CD6 3.7 x 10-23 1.13 
11q23.3 CXCR5 3.0 x 10-15 1.10 
12p13.31 TNFRSF1A 6.7 x 10-28 1.14 
12q14.1 METTL1, CYP27B1 5.0 x 10-11 1.23 
14q24.1 ZFP36L1 9.3 x 10-12 1.11 
14q31.3 GALC 2.4 x 10-20 1.32 
16p13.31 CLEC16A 6.4 x 10-46 1.20 
16q24.1 IRF8 5.9 x 10-12 1.15 
17q21.2 STAT3 3.7 x 10-20 1.12 
19p13.3 TNFSF14 1.7 x 10-24 1.16 
19p13.2 TYK2 1.8 x 10-14 1.29 
19q13.33 DKKL1 5.7 x 10-15 1.11 
20q13.2 CYP24A1 2.0 x 10-13 1.09 
20q13.12 CD40 7.7 x 10-16 1.11 
22q11.21 MAPK1 5.5 x 10-16 1.10 
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Table 1. The most well-established MS-associated loci. The following loci have been 
identified in at least two independent genome-wide studies. One or several genes are listed 
for each locus, based on proximity to the associated SNP. The SNP with the highest p-value 
after combining available datasets is listed for each loci. All listed SNPs are intronic or 
intergenic, with the exception of rs41286801, which is located in the 3’ untranslated region of 
EVI5. Adapted from Bashinskaya, et al.83. 
1.1.4 MS - pathogenesis 
MS is widely regarded as a primary immune mediated disease84, a hypothesis supported 
among other things by: 
- MS lesions are characterized by early T cell infiltration85,86, 
- the vast majority of associated genetic variants are in close proximity to immune 
genes, 
- and successful MS treatments all target the immune system. 
Furthermore, MS is considered a primary autoimmune disease, supported among other things 
by: 
- the most influential genetic risk factor is localized to the MHC, 
- autoreactive T and B cells are frequently identified in MS patient blood samples, 
- the many observed similarities to the autoimmune disease model EAE. 
 
However, the primary autoantigen or antigens responsible for MS onset are not known. 
Unlike established autoimmune diseases like myasthenia gravis and neuromyelitis optica, 
which are known to be caused by autoreactive antibodies to acetylcholine receptors at the 
neuromuscular junction87,88 and astrocytic water channel, aquaporin-489,90, respectively, MS 
can formally not be defined as a primary autoimmune disease. For the sake of discussion, an 
alternative hypothesis states that the disease trigger is neurodegeneration followed by 
secondary inflammation and autoimmunity. Any autoreactive T or B cells detected could be a 
result of bystander activation and may not even be driving the disease at all. 
Histopathological analysis of some of the earliest available MS lesions demonstrate cases of 
oligodendroglial pathology in the complete absence of immune infiltration91. 
Assuming a primary immunological trigger, two hypotheses exist regarding its nature: The 
immune system is triggered in the CNS or in the periphery. Postulated CNS triggers include a 
local viral infection. The hypothesis of a peripheral immune cell activation followed by 
trafficking to and reactivation in the CNS is analogous to the pathogenesis of the MS disease 
model EAE. Postulated peripheral triggers are viral or bacterial infection leading to cross-
reactive immune cell specificities by molecular mimicry92–94, bystander activation95,96 or T 
cells bearing dual TCRs97. The case of Human herpes virus-6 (HHV-6) is interesting. Virions 
have been identified in MS lesions and sequence similarities with myelin basic protein 
(MBP) have experimentally been shown to result in T cell cross-reactivity94. This is example 
of molecular mimicry. Moreover, HHV-6 and other enveloped viruses have the capacity to 
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take up host proteins, which is another plausible mechanism how tolerance to self may be 
broken98. 
The primary feature of MS neuropathology is the MS plaque or lesion. These are confluent 
areas of demyelination, inflammation, oligodendrocyte and neuronal degeneration, and 
astrogliosis99–102. The lesions are found in both white and grey matter in the brain as well as 
in the optic nerves and the spinal cord. The inflammatory component, driven by adaptive 
immunity, is most pronounced in the early stages of disease. Early lesions are characterized 
by a permeable BBB, of which the radiologic correlate is contrast-enhancing lesions on MRI. 
These lesions tend to be dominated by macrophages and T cells, with CD8+ T cells 
outnumbering CD4+ T cells. It has, furthermore, been shown that CD8+ T cells isolated from 
MS lesions exhibit clonal expansion more frequently than CD4+ T cells103. B cells and 
plasma cells are also identified but to a lesser extent.  
As the disease progresses, inflammation becomes less pronounced and fewer new lesions 
appear. At this stage, neuropathology is primarily characterized by brain atrophy and an 
cortical lesions, possibly driven by innate immunity and/or dysfunction in the neurons 
themselves104–106. Neuroaxonal loss is eventually noticeable also in so called normal 
appearing white matter and general brain atrophy accelerates seemingly independently of 
lesions and clinical relapses107–110. Measurement of brain atrophy has become an important 
parameter in clinical trials but can be to some degree confounded by the reduction in white 
matter volume due to resolution of inflammation, termed pseudoatrophy111. The proportion of 
B cells and plasma cells also increase during the later stages of disease112,113. Tertiary 
lymphoid structures in the meninges become more prevalent as well. In late disease 
inflammation appears to be contained within the CNS, as few immune cells are recruited 
from the periphery. This development mirrors the clinical transition from relapsing remitting 
disease to progressive disease. The CNS-intrinsic inflammatory component and the 
associated brain atrophy are essentially not influenced by established MS treatments. This 
lack of effective treatment options for progressive MS is one of the biggest and most pressing 
challenges facing research in this field as well as clinical practice.  
Moreover, there are other neurological symptoms associated with MS that are not purely 
focal in nature and therefore somewhat neglected, perhaps due to difficulties in objectively 
assessing them. A form of primary fatigue is commonly seen which can be very 
debilitating114. Interestingly, also symptoms like fatigue and depression may be a 
manifestations of immunological processes in the CNS115,116. 
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Figure 2.  The current view of MS pathogenesis 
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1.1.5 Experimental autoimmune encephalomyelitis (EAE) 
Many pathophysiological research questions regarding MS have been addressed primarily in 
animal models. This has been necessitated by: the very limited access to human CNS tissue, 
large disease heterogeneity, and long preclinical disease stage. The most common disease 
model is EAE, which is induced in susceptible laboratory animals by breaking 
immunological tolerance to a CNS autoantigen.  
EAE can be viewed as a group of models with differing characteristics depending on for 
example the species used, the autoantigen used, if active or passive immunization is 
performed. Several of the candidate autoantigens for MS have been used to induce EAE, for 
example MBP, myelin oligodendrocyte glycoprotein (MOG), and proteolipid protein (PLP). 
Interestingly, different peptides from these proteins can vary greatly in their encephalitogenic 
potential117–119. In work presented in this thesis, active immunization with MOG in C57BL/6 
mice or Dark Agouti (DA) rats were used. Compared to most other proposed autoantigens in 
MS, MOG is a minor component of myelin. However, it is highly encephalitogenic in most 
laboratory animals and induction of EAE with whole myelin in MOG-deficient mice gives 
mild disease, showing that it is a major pathogenic component in autoimmunity towards 
myelin in mice120. Study results are inconclusive regarding the role of reactivity to MOG in 
MS patients121–123.  
To induce EAE, the autoantigen is emulsified in oil and injected subcutaneously to produce 
local slow release of antigen in a pro-inflammatory environment. C57BL/6 mice are 
relatively resistant to disease induction and MOG-EAE in this strain requires addition of 
heat-killed mycobacteria in the adjuvant as well as systemic administration of pertussis toxin, 
the latter repeated after 2 days. Mycobacteria are a classic inducer of Th1 type immunity. 
Interestingly, EAE can also be induced with the mycobacteria exchanged for Citrobacter 
rodentium, an inducer of Th17 type immunity, yielding a less severe disease course124. 
Proposed mechanisms of action for the pertussis injections in the context of EAE include: i) 
transiently opening the BBB, ii) inhibition of regulatory T cell activity, and iii) promotion of 
Th17 differentiation125–127. Once the emulsion is injected, dendritic cells (DC) take up the 
antigen, are activated by ligation of pattern recognition receptors (PRR), upregulate MHC 
class II, and migrate to the draining lymph nodes where they present the antigen to circulating 
CD4+ T cells. The T cells are activated, expand in numbers, reenter the circulation, and 
infiltrate the CNS where they are reactivated by local APCs.  The resulting inflammation 
leads to recruitment of monocytes, neutrophils, CD4+ T cells, and CD8+ T cells. Naïve T cells 
with other specificities are also recruited, which can become activated through epitope 
spreading128,129. EAE can also be passively induced by adoptive transfer of activated 
encephalitogenic T cells.   
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1.1.6 T and B lymphocyte effector mechanisms in MS and EAE 
Although many immune cells have been shown to influence EAE and similarly been 
implicated in MS, CD4+ T cells have received the most attention. The relative importance of 
T helper cell subsets and their effector molecules in EAE and MS has been debated for some 
time130.  
EAE was initially believed to be driven by Th1 cells and the signature cytokine IFNγ. This 
was partly based on the ability of Th1 cells to induce passive EAE131, identification of IFNγ 
secretion from T cells infiltrating the CNS, and the observed resistance to EAE in mice with 
targeted deletion of tbet, master transcription factor for Th1 cells, as well as mice with 
deletion or antibody-mediate neutralization of subunit p40 of Th1 promoting cytokine IL-
12132–134. Consequently, MS has also been viewed upon as a Th1 mediated disease, which is 
supported by the detection of IL-12 and IFNγ in lesions and CSF from MS patients135,136. 
Furthermore, administration of IFNγ to MS patients in the setting of a small trial caused 
disease exacerbation137. It was therefore surprising when subsequent studies showed that the 
other IL-12 subunit, p35, as well as IFNγ was redundant or even protective in EAE138–141. The 
explanation for these contradictory findings came when it was shown that IL-12p40 was a 
common subunit for both IL-12 and IL-23, the latter a factor that promotes Th17 
differentiation142. Mice deficient in IL-23 subunit p19 were shown to be resistant to EAE 
induction, which ignited great interest in Th17 cells in EAE and MS. Just like IFNγ, none of 
the signature cytokines of the Th17 subset is necessary for EAE induction143–145.  
There is currently renewed interest in the cytokine granulocyte-macrophage colony-
stimulating factor (GM-CSF), which appears to be critical for EAE induction146,147. More 
recent reports have shown that GM-CSF production by both Th1 and Th17 is necessary for 
disease induction148,149.  However, in C3HeB/Fej mice, which differently from other mouse 
strains develop inflammation in both spinal cord and brain, full EAE susceptibility has been 
reported despite absence of GM-CSF150. It may be so, that no single mediator is completely 
necessary for EAE or MS to develop.  
In contrast, an increasing number of reports suggest that the balance between 
encephalitogenic Th1 and Th17 responses influences the pathological manifestations of EAE 
and MS151. In EAE, an increased Th17:Th1 ratio is associated with inflammation 
predominantly in the brain and a decreased Th17:Th1 ratio favors inflammation in the spinal 
cord152. Several studies in mouse EAE have later shown that IFNγ acts to suppress 
inflammation in the brain but not in the spinal cord153,154. In contrast, a recent study showed 
that myelin specific peripheral blood T cells from MS patients with predominant spinal cord 
inflammation had higher Th17:Th1 compared to patients with predominant brain 
inflammation155. It is still unclear whether the T cell phenotype in the periphery accurately 
reflects that in the CNS or is inverted as Th1 cells are mobilized to brain, in which case the 
human data would be consistent with previous mouse data. It is also not known whether the 
spinal cord and brain have different susceptibility to Th1 and Th17 responses or if the T cells 
locally are differentially polarized by the respective microenvironment. There is mouse data 
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that support the first scenario, using the C3HeB/Fej mice. After immunization the CD4+ T 
cells in these mice recognize two distinct MOG epitopes, MOG79-90 and MOG97-114. Adoptive 
transfer of only MOG79-90 specific T cells predominantly yields inflammation in the spinal 
cord whereas transfer of MOG97-114 T cells predominantly results in inflammation in the 
brain156. Moreover, the MOG97-114 specific T cells displayed a higher Th17:Th1 ratio after in 
vitro stimulation, compared to the MOG79-90 specific T cells. When drawing conclusions 
regarding the effects of IFNγ and IL-17 in EAE one must bear in mind the plasticity of T 
helper cells in general and in particular that there seems to be a switch from Th17 to Th1 
polarization after entry in to the CNS157. 
The involvement of B cell in MS has not been studied to the same extent as that of T cells. 
Observations that support a role for B cells in MS pathogenesis include: 
- identification of myelin specific antibodies in CSF and blood from MS patients158,159, 
- presence of oligoclonal intrathecal antibodies in most MS patients, which serves as a 
useful diagnostic biomarker, 
- and evidence for clonal expansion of B cells in the CNS of MS patients160,161, 
- depletion of B cells using anti-CD20 monoclonal antibodies is one of the most 
effective treatments for both RRMS and progressive MS162–166. 
Interestingly, anti-CD20 treatment does not deplete plasma cells, making it plausible that the 
B cells influence MS by other mechanisms than production of antibodies, for example 
cytokine production or antigen presentation. Both of these explanations have received 
experimental support. The effect of anti-CD20 treatment in mice is dependent on B cell IL-6 
production, which promotes Th7 responses167. B cells are the most abundant MHC class II-
expressing cell in the naïve mouse CNS168. In the same report, it is further shown that in the 
absence of B cells, adoptively transferred T cells infiltrate the CNS but have a diminished 
capacity to recruit more cells from the periphery. 
1.1.7 MS - treatments 
After interferon beta-1a was approved in the mid-nineties, as the first drug to treat MS169, the 
treatment options have expanded greatly. More than 10 disease-modifying drugs have been 
approved to date. 
Interferon beta-1a is a naturally occurring cytokine with antiviral and anti-proliferative 
effects. It is available as subcutaneous or intramuscular injections for the treatment of MS. A 
pegylated form is now available that only needs to be administered every two weeks170. Many 
immunological effects of Interferon beta-1a treatment have been observed but their relative 
contribution to the treatment effect is not known171–174. It has a modest effect on relapse rate 
and MRI activity but no effect on disease progression. Side effects are mild and mainly 
involve influenza-like symptoms and skin-reactions at the injection site. 
Glatiramer acetate is a mixture of polypeptides that includes four amino acids that recur in 
the MS candidate autoantigen MBP. Several mechanisms of action have been proposed e.g. 
partial induction of tolerance in MBP-specific T cells, thus acting as an altered peptide 
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ligand175,176, and induction of glatiramer acetate-reactive Th2 T cells177. Glatiramer acetate is 
administered daily as a subcutaneous injection and the efficacy and safety profile is similar to 
interferon beta-1a178. 
Teriflunomide is taken orally and inhibits dihydro-orotate dehydrogenase, a key enzyme in 
the de novo pyrimidine synthesis pathway. It is believed to inhibit proliferation of activated T 
and B cells without affecting the homeostatic proliferation of resting lymphocytes179. As a 
result, it does not increase occurrence of serious infections180. It also induces an anti-
inflammatory shift in T cell polarization and immunoglobulin isotypes. The efficacy and 
safety profile is similar to interferon beta-1a181. 
Dimethyl fumarate is a small molecule derived from fumaric acid, an intermediate in the 
citric acid cycle. The mechanism of action is not clear but may involve an antioxidant effect 
by activation of the transcription factor nuclear factor E2 related factor 2 (Nrf2) and also an 
anti-inflammatory effect through inhibition of the transcriptional regulator NF-κB. It is taken 
orally and reduces relapse rate and MRI activity182,183. A reduction in disease progression, i.e. 
increased time to disability, was shown in one trial182. A small number of cases of 
progressive multifocal leukoencephalopathy (PML), an adverse effect with high mortality 
caused by reactivation of latent John Cunningham (JC) virus infection in the CNS, has been 
reported in the treatment of MS patients with dimethyl fumarate184. 
Fingolimod is a sphingosine-1-phosphate analogue that is taken orally. It acts as an antagonist 
of sphingosine-1-phosphate receptors. Fingolimod ligation leads to the receptor being 
internalized and degraded. As lymphocytes depend on cell surface expression of sphingosine-
1-phosphate receptors to egress from lymphoid tissue, this treatment result in them being 
trapped and consequently less lymphocytes will be present in the circulation. Like dimethyl 
fumarate, fingolimod has been shown to reduce disease progression in one trial185,186. In a 
head to head comparison with interferon beta-1a, fingolimod treatment resulted in 
approximately half the number of relapses per year187. But fingolimod treatment is on the 
other hand associated with more disconcerting side effects, like bradycardia, heart block, 
macular edema, and infections as well as some very serious rare adverse effects, most 
notably, generalized varicella zoster infection, herpes encephalitis and PML. 
Natalizumab is a humanized monoclonal antibody that blocks α-4 integrin, which is a 
component of very late antigen 4 (VLA-4) present on lymphocytes. It is given intravenously 
every 4 weeks. Natalizumab inhibits the interaction between VLA-4 and its ligand, vascular 
cell adhesion molecule 1 (VCAM-1), expressed on endothelial cells, thus preventing 
lymphocytes from crossing the blood-brain barrier. It is one of the most effective disease 
modifying treatments for MS with a clear effect on disease progression shown in one trial188. 
However, more than 600 MS patients have developed PML during natalizumab treatment 
with a mortality rate of more than 20 %189. By excluding patients with high JC virus-antibody 
blood titers or increasing monitoring by MRI, the risk of PML has significantly been 
reduced190,191. 
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Alemtuzumab is a humanized monoclonal antibody directed against CD52, which is 
expressed on lymphocytes and monocytes. It is given intravenously for five consecutive days 
and then another three consecutive days a year later. This results in a very long-lasting 
reduction in B and T cells, with T cells recovering slower than B cells. One trial has shown a 
significant effect on disease progression192. The safety profile is an issue, however, which 
makes frequent clinical monitoring necessary. Apart from an expected increase in 
susceptibility to infections, approximately 30 % develop secondary autoimmune disorders, 
primarily affecting the thyroid gland192,193.  
Daclizumab is a humanized monoclonal antibody directed against CD25, a component of the 
IL-2 receptor, thus acting as an IL-2 antagonist. It not only reduces the circulating levels of 
CD4+ and CD8+ T cells but also expands a population of CD56bright natural killer (NK) cells, 
which may be more important for the clinical effect in MS194. Monthly subcutaneous 
injections of daclizumab has been shown to be superior to interferon beta-1a but does not 
reduce disease progression. It is a relatively new drug that has recently been approved in the 
USA and Europe for the treatment of MS173. 
Ocrelizumab is a monoclonal antibody directed against CD20, which is expressed on B cells. 
It was developed in light of the efficacy of rituximab in MS162,164,195 and the CD20 epitopes 
of the two antibodies overlap. It acts by depleting CD20-expressing cells, i.e. B cells but not 
plasma cells. Ocrelizumab is a humanized antibody, thus expected to be less immunogenic 
compared to rituximab, which is a mouse chimeric antibody. Ocrelizumab is recently 
approved in the USA for the treatment of MS and is also the first treatment approved for the 
treatment of primary progressive MS165,196. 
 
1.2 IMMUNOLOGY 
The research presented in this thesis is mainly within the field of immunology, in regards to 
questions addressed and methods used. Now follows an overview of the immunological 
scope of the work. 
The immune system consists of a network of specialized cells and molecules that have 
evolved to protect multicellular organisms from pathogens. These cells and molecules 
typically interact in complex and dynamic ways, of which our understanding is far from 
complete, despite having accumulated a tremendous amount of detailed knowledge. In 
addition to fighting off infections, the immune system suppresses the development of cancer 
and has also been shown to interact with other body systems, such as the metabolic, 
endocrine, and nervous system. However, the work discussed in this thesis will be centered 
on the situation when disease is caused by the immune system itself i.e. inflammatory and 
autoimmune diseases. 
It is useful to think of the immune system as consisting of two lines of defense against 
invading pathogens - innate and adaptive immunity. Adaptive immunity is more effective at 
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clearing infections but takes several days to develop. In the meantime, innate immune 
mechanisms will attempt to stop or at least delay the infection and simultaneously start the 
process of mounting an adaptive immune response directed specifically to the invading 
microorganism. The two systems do not work in isolation, however. Signals from the innate 
immune system activate and shape the adaptive immune response and a major part of 
adaptive effector mechanisms is to focus and amplify the activities of innate immune cells.  
1.2.1 Innate immunity 
Key elements included in the concept of innate immunity are:  
- Physical barriers – most prominently the epithelial layers lining surfaces facing the 
outside world, 
- Chemical and mechanical barriers - such as acidic pH, antimicrobial peptides, and 
secretions with directional flow that wash away invaders.  
- Inflammatory response – characterized by recruitment of fluid, molecules, and cells to 
the site, thus signaling to the rest of the body that a threat is present, 
- Phagocytosis – rapid ingestion of bacteria by cells such as neutrophils and 
macrophages. 
1.2.1.1 Epithelial barrier of the skin 
The skin consists of the epidermis and underneath it, the dermis. The epidermis is composed 
of several layers of tightly packed cells of which the outermost layers are dead cells filled 
with keratin that makes the skin a waterproof barrier. The dermis is mostly connective tissue 
and contains blood and lymphatic vessels, hair follicles, sweat and sebaceous glands, as well 
as immune cells such as DCs, macrophages, and mast cells. 
1.2.1.2 Antimicrobial proteins and peptides 
Epithelial cells at barrier surfaces constitutively produce a broad range of molecules that kill 
or inhibit growth of bacteria or fungi. These show some degree of specificity, seen for 
example in the case of psoriasin, which is expressed in the skin. This antimicrobial protein 
does not affect skin commensal Staphylococcus aureus but rapidly kills intestinal commensal 
Escherichia coli if it happens to end up on the skin. The related antimicrobial, also from the 
family of S-100 proteins, does however kill both bacterial species197. Antimicrobial peptides 
are generally smaller than 100 amino acids and are a primitive form of innate immunity even 
found in plants and some fungi. The main types found in humans are the defensins and 
cathelicidin. They can disrupt membranes of bacteria and fungi and then enter the cell where 
they exert other effects such as inhibiting the synthesis of DNA, RNA, and proteins198. 
1.2.1.3 Toll-like receptors 
Inflammation and phagocytosis depend on the recognition of conserved structural elements 
present on pathogens but absent in humans, so called pathogen associated molecular patterns 
(PAMP). PAMPs are recognized by a wide range of extracellular and intracellular pattern 
recognition receptors (PRR), that help the immune system to distinguish between what is self 
(part of the body) and non-self (an invader that should be eradicated). There are a number of 
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PRR-families but the best characterized are the toll-like receptors (TLR)199,200. Ten TLRs 
have been identified in humans, each with specificity for certain conserved microbial 
elements. The TLRs are either cell surface receptors or localized to intracellular vesicles and 
they are most highly expressed by sentinel cells like macrophages and dendritic cells. TLRs 
are expressed in the CNS by microglia, the primary resident sentinel cell, but also by 
astrocytes, oligodendrocytes and neurons201. 
1.2.1.4 Chemokines 
The chemokines are a family of small proteins that are secreted into the extracellular space 
for the purpose of attracting other cells. A concentration gradient is established from the site 
of production that attracts cells bearing the corresponding chemokine receptor, a process 
called chemotaxis. Specificity of leukocyte chemotaxis is achieved by the existence of many 
different chemokines and chemokine receptors that are selectively expressed in a dynamic 
way. The chemokines are divided into two groups: the homeostatic chemokines, which are 
continuously secreted in certain tissues and facilitate immune cell surveillance in the steady 
state, and the inflammatory chemokines, which are induced as a part of an inflammatory 
response. The B cell-attracting chemokine CXCL13 has attracted much attention as a 
potential biomarker for MS and may promote the formation or tertiary lymphoid follicles in 
the CNS characteristic of progressive disease202–206. 
1.2.1.5 Innate immune cells 
All immune cells as well as erythrocytes and thrombocytes develop from the same origin, the 
hematopoietic stem cell, which resides in the bone marrow. When a hematopoietic stem cell 
starts differentiating, the first fate-determining step is to become either a common myeloid 
progenitor that later gives rise to erythrocytes, granulocytes, monocytes, and macrophages or 
to become a common lymphoid progenitor that later gives rise to T cells, B cells, and NK 
cells. Myeloid cells and NK cells are part of the innate immune system. 
Neutrophilic granulocytes (neutrophils) constitute the majority of circulating immune cells. 
They are the first cells to be recruited during an immune response and the rapid increase in 
circulating granulocytes is used clinically as an indication of infection. Neutrophils have in 
their cytoplasm granules that contain various preformed proteins ready to be expelled, some 
resulting in direct damage to pathogens and others resulting in recruitment of other cells, for 
example macrophages and more neutrophils. 
Monocytes constitute 5-10 % of circulating cells. They are a heterogeneous population that 
can be divided into inflammatory monocytes, which enter tissues rapidly and can differentiate 
into macrophages with high phagocytic capacity, and patrolling (non-classical) monocytes, 
which may in contrast act to dampen inflammation207. DCs are also a heterogeneous 
population of cells that can develop from either the myeloid progenitor, lymphoid progenitor 
or directly from monocytes. They phagocytose pathogens in the tissues, migrate to secondary 
lymphoid organs and present antigens to CD4+ T cells to initiate an adaptive immune 
response. Other cells that can act as APCs are macrophages and B cells.  
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1.2.2 Adaptive immunity 
The T and B lymphocytes are the orchestrators of adaptive immune responses. They have 
several important features in common. Randomly assembled antigen-receptors, stringent 
selection to exclude autoreactive clones, high threshold of activation, and immunological 
memory that enables a more rapid and effective response the next time the same antigen is 
encountered. 
1.2.2.1 T cells 
T cells are divided into T helper (Th) cells, distinguished by cell surface expression of CD4 
and cytotoxic T cells (Tc) distinguished by cell surface expression of CD8. Th cells recognize 
antigens bound to MHC class II on APCs and primarily act by releasing cytokines that 
activate other cells of the immune system. Tc cells recognize antigens bound to MHC class I 
on most nucleated cells and primarily act by killing the cells displaying the antigen. Th cells 
have been the subject of intense research aiming to characterize distinct subsets based on the 
cytokines they produce and the signaling events that lead to their differentiation. In relation to 
autoimmune disease, the Th1 and Th17 subsets are most frequently discussed and are 
generally regarded as pathogenic. In relation to protective immunity to infection, Th1 cells 
mount immune responses to intracellular pathogens and Th17 appears to be important for 
extracellular pathogens and fungi. 
Another group of T cells frequently discussed in relation to autoimmune disease is the 
regulatory T cells, which by different means act to suppress lymphocyte activation and 
consequently inflammation. 
All the T cells discussed so far have a TCR that is composed of an alpha chain and a beta 
chain, sometimes called αβT cells to distinguish them from T cells with a TCR composed of 
a gamma chain and a delta chain. The γδT cells have features of both adaptive and innate 
immune cells and are currently the subject of much research but their role in autoimmune 
disease is only beginning to be elucidated. 
1.2.2.2 B cells 
B cells include B-1 B cells, B-2 B cells, marginal zone B cells, and regulatory B cells. B-2 B 
cells are by far the most common B cell, and is usually implied when discussing simply B 
cells. Although B cells also secrete cytokines and act as antigen presenting cells, the major 
activity is to produce antibodies. They display on their surface a B cell receptor, which has 
the same specificity as the antibodies that they will produce if activated. Once B cells exit the 
bone marrow they are directed towards secondary lymphoid organs as a consequence of their 
expression of the chemokine receptor CXCR5 whose ligand, CXCL13, is constitutively 
secreted there by follicular dendritic cells. The B cell receptors bind antigens independently 
of any other cell type but in general they need help from T cells that recognize epitopes from 
the same microbe/source, to become activated. Once activated, some B cells will go through 
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a processes in the lymphoid organ to optimize antibody specificity (somatic hypermutation) 
and to change the type of antibody produced (isotype switching). 
 
1.3 INTERLEUKIN-22 
1.3.1 The IL-22-system 
Cytokines are soluble mediators that all cells of the immune system use to some extent to 
shape the immune response. The term interleukin was proposed in 1979 as a classification of 
cytokines that are secreted by leukocytes and mediate signals to other leukocytes208. As new 
cytokines were discovered that fit this criterion they were named interleukin and a number, 
based on the order they were discovered. The definition of interleukins is however somewhat 
outdated, because as more knowledge has been gained about these cytokines it has become 
clear that also other cells produce them and respond to them. 
1.3.1.1 IL-22 
IL-22 was described in 2000 as a cytokine expressed by T cells209. It is now known that many 
immune cells of both the innate and adaptive immune system produce IL-22210. Most well 
studied is the contribution from Th17211–214 cells and innate lymphoid cells215–218. Moreover, 
a distinct T helper subset that expresses IL-22 but not IFNγ, IL-4, or IL-17 has been 
described, termed Th22219–221. Fate-mapping shows that in vitro generated Th22 cells have 
not previously expressed IL-17222. They have a marked plasticity towards IFNγ production 
under Th1 polarizing conditions. IL-22 expression in non-hematopoietic cells has been 
reported as well223. Unlike most other cytokines, IL-22 acts primarily on non-hematopoietic 
cells224,225.  
1.3.1.2 IL-22R 
The IL-22 receptor (IL-22R) is a heterodimer consisting of the subunit IL-22R1 (transcribed 
from the gene IL22RA1) and the ubiquitously expressed IL-10R2 (transcribed from the gene 
IL10RB)226–230. The receptor is expressed on epithelial and parenchymal cells in a range of 
organs, most notably the barrier surfaces skin, lungs and gastrointestinal tract, but also other 
organs like kidney, pancreas, thymus, liver and synovial tissue217,231–234. There are also 
reports of IL-22R expression on immune cells but these findings need further confirmation 
and characterization before the significance of this can be appropriately assessed235–242. 
1.3.1.3 IL-22BP 
The soluble binding protein IL-22BP binds to IL-22 with very high affinity243,244. The binding 
site of IL-22BP on IL-22 overlaps with that of IL-22R1, thus effectively stopping IL-22 from 
activating the receptor230. IL-22 is one of few cytokines that have a dedicated inhibitor, 
implying that it has been particularly important for the organism to be able to turn off 
unwarranted IL-22 signaling at certain time points of an immune reaction or at certain 
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locations245. The cellular source of IL-22BP has mostly been reported as being APCs, but 
recently also T cells and eosinophils have been shown to express IL-22BP specifically in the 
gut246–250. 
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Figure 3. IL-22 signaling 
  
1.3.2 IL-22 physiology and pathophysiology   
Typically, the effects of IL-22 on tissues can be summarized as proliferative, regenerative, 
and tissue protective but it also induces innate immune mechanisms such as anti-microbial 
peptides and chemokines210,251.  IL-22 levels have been correlated to many inflammatory 
states and expression is essentially always upregulated in these studies. 
1.3.2.1 skin 
There is great interest in the role of IL-22 in the skin and all the effects mentioned above have 
been demonstrated in IL-22-stimulated keratinocytes. Moreover, IL-22 results in delayed 
keratinocyte differentiation, which is one of the hallmarks of the pathology of psoriasis212,252–
255.  
1.3.2.2 liver 
In the liver, IL-22 has been shown to induce production of acute phase reactants by the 
hepatocytes but also confers upon them protective and regenerative effects in several 
experimental models of injury such as infection, alcohol mediated damage, autoimmunity, 
and ischemia256–262.  
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1.3.2.3 thymus 
After radiation injury to the thymus IL-22 acts to regenerate the tissue and restore function 
relating to T cell development263.  
1.3.2.4 gastrointestinal tract 
In the gastrointestinal tract, IL-22 has an important role in maintaining epithelial barrier 
integrity. One study show that innate lymphoid cell (ILC) derived IL-22 contains Alcaligenes 
species in the gut and thus prevents systemic inflammation217. However, the consequences of 
IL-22 deficiency is much greater in the context of intestinal inflammatory pathology, 
exemplified by markedly exacerbated colitis in Il22-/- mice infected with Citrobacter 
rodentium compared to wild type mice264–268. IL-22 supports the epithelial cells lining the 
gastrointestinal tract by inducing expression of genes that regulate proliferation, wound 
healing, and apoptosis. If the proliferative effect of inflammation-induced IL-22 is not limited 
by IL-22BP neoplasia can result, as shown in a mouse model of inflammation induced 
tumorigenesis248. IL-22 may also regulate tight junctions between the epithelial cells269. 
1.3.2.5 CNS 
The potential effect on tight junction integrity is interesting in relation to neuroinflammation. 
One report has shown that both IL-17 and IL-22 are able to disrupt BBB tight junctions270. 
This implies that IL-22 may act to increase susceptibility to and/or severity of 
neuroinflammation. However, IL-22 deficient mice have the same disease course of EAE as 
wild type mice145. Another report has shown that astrocytes express IL-22R and receive 
trophic support from IL-22 and yet another reports IL-22R expression on oligodendrocytes 
and increased apoptosis upon IL-22 stimulation271,272. So, the role of IL-22 in 
neuroinflammation is still very much unclear. 
 
1.4 SKIN INFLAMMATION 
1.4.1 Structure of the skin 
The skin consists of three layers: epidermis, dermis, and subcutis. The epidermis is mainly 
composed of keratinocytes with the important addition of Langerhans cells, a population of 
skin-resident DCs. Keratinocytes differentiate as they move from the most basal layer of the 
epidermis towards the surfaces of the skin at which point they lose their nuclei and organelles 
and become interlocked with each other in a highly hydrophobic matrix. The dermis consists 
mostly of collagenous connective tissue interspersed with blood vessels, immune cells, hair 
follicles, sweat glands and sebaceous glands. Subcutis, also called hypodermis, is a layer of 
fat that makes up the innermost layer of the integumentary system. 
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1.4.2 Immune system of the skin 
Skin associated lymphoid tissue, just like its counterpart in the intestines, is in a state of 
relative tolerance necessitated by symbiosis with abundant microbiota273. A prominent 
feature of the immune compartment of the skin is a population of resident effector memory T 
cells that are believed to be non-recirculating. They bear the skin migratory receptor 
cutaneous lymphocyte antigen (CLA), which binds to E-selectin on cutaneous blood vessels. 
Furthermore, expression of chemokine receptor CCR10 enables homing towards CCL27 
produced by keratinocytes during non-inflammatory states. Keratinocytes are major 
producers of chemokines upon inflammation. In the case of a Th1 response, IFNγ induces 
keratinocyte production of CXCL9, CXCL10, and CXCL11, which recruit more Th1 cells. 
Similarly, IL-17 yields production of CCL20, CXCL1, CXCL2, and CXCL8, which recruit 
Th17 cells and neutrophils. The major APCs of the skin are Langerhans cells and myeloid 
DCs.  
1.4.3 Psoriasis 
The prevalence of psoriasis shows great regional variability but is approximately 2-3 % in 
Europe and North America273. Psoriasis vulgaris is the most common type and presents with 
large plaques of erythematous desquamating lesions characterized by infiltration of immune 
cells. The severity of psoriasis is commonly assessed by approximating the percentage of the 
body surface that is affected. The disease etiology is complex and not fully understood. 
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2 AIMS OF THE THESIS 
 
When the work included in this thesis started in 2010, rat Il22ra2 had attracted our interest as 
the possible mediator of an effect on EAE mapped to a locus on chromosome 1246. Moreover, 
IL22RA2 had also been defined as the candidate gene for the MS-associated SNP 
rs1706609644. The literature on IL22RA2 and its gene product IL-22BP was scarce and no 
other links to neuroinflammation had been reported. The literature on IL-22 was much more 
extensive, but still only a few indications of what role this cytokine may have in MS or EAE 
were available. Most notably, there was the negative report in which Il22-deletion was shown 
to have no effect on EAE in mouse145, which suggested IL-22 independent effects of IL-22BP 
in the context of neuroinflammation. 
The overall aim of this thesis was to understand the role of IL-22BP in MS pathogenesis. 
 
The specific aims were: 
1. to determine if deletion of Il22ra2 or specific reduction of its expression influence 
EAE, 
 
2. to determine if any such influence is dependent on the presence of IL-22, 
 
3. to characterize IL-22BP/IL-22-mediated effects on the immune system, 
 
4. and to detemine if the genotype of MS-risk variant rs17066096 influences 
IL22RA2 expression. 
 
 
 
 
Figure 4. MS-associated SNP rs17066096 is located approximately 14 kb downstream from 
IL22RA2. Blue bars represent exons.
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3 METHODOLOGICAL CONSIDERATIONS 
 
A discussion of the methods that were used in this thesis follows below. Detailed descriptions 
are found in the respective materials and methods sections of paper I-IV. 
 
Ethics statement 
All procedures performed using animals, human samples, or clinical data were approved by 
the appropriate ethical review boards. All human subjects that have contributed samples to 
these studies have given their written or oral consent prior to inclusion. 
 
Mouse and rat strains 
Specific disruption of a gene or gene product of interest, while keeping all else equal is a 
well-tried principal of experimental research aiming to understand biological processes. With 
such tools at your disposal, you can address the role of a biomolecule or cell type in specific 
contexts. There are a number of principally different genetic models available with distinct 
advantages and disadvantages, meaning that careful attention must be paid to the 
requirements of the project.  
In our laboratory, we have a long tradition of working with rats, mainly for the purpose of 
locating and studying natural genetic variants that influence EAE. This can be done by 
intercrossing inbred rat strains with different susceptibility to EAE, thus producing 
heterogeneous offspring as a result of random recombinations during meiosis. Inducing EAE 
in a large number of offspring enables linkage analysis in a way similar to how genes 
responsible for Mendelian genetic diseases are localized to a specific region of a 
chromosome. The effect of the linked region can then be confirmed by producing a congenic 
strain. This is done by intercrossing the two parental strains and repeatedly selecting 
offspring with the chromosomal fragment of interest and backcrossing these with wild type 
rats of the other parental strain. Using this approach, we reported an effect on EAE that came 
from a region in the beginning of chromosome 1 including the gene Il22ra2. This was 
published before the work on this thesis started246.  
For the follow-up studies included in this thesis, we commissioned a company to produce an 
inducible Il22ra2-knockdown rat strain that makes use of tetracycline-controlled 
transcriptional activation. Administration of the tetracycline-analogue doxycycline in the 
drinking water induces expression of a short hairpin RNA (shRNA) that specifically 
hybridizes with Il22ra2 mRNA that subsequently becomes degraded by the cellular 
microRNA machinery. This results in a significant drop in Il22ra2-mRNA levels within 1-2 
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days after the start of doxycycline administration yielding knockdown efficiencies in the 
range of 50-90 %. From our perspective, the advantages of this genetic model were:  
- that we continued working with a rat strain of the same genetic background as the one 
in which we had observed an effect on EAE coming from chromosome 1, 
- we avoided potential compensatory effects by the complete lack of Il22ra2 from 
conception to adult rat, 
- we could study the role of Il22ra2 at different time points during the disease course, 
- reducing expression of a gene rather than deleting it completely more closely 
resembles the situation of human natural genetic variation that we ultimately want to 
understand, 
- and that gene targeting in rat was not available at the time.  
The major disadvantage of working with rats in general when investigating disease 
mechanisms is the scarcity of reagents and commercially available transgenic strains. 
Moreover, the literature is dominated by information from studies of mice, which can not 
always be extrapolated to rat. 
To expand the number of tools available to us, we decided to also study Il22ra2 using mice in 
parallel and acquired a conventional Il22a2 knockout mouse strain. This enabled us to later 
also acquire an Il22 conditional knockout mouse strain and produce the Il22ra2/Il22 double 
knockout used in paper III. 
 
EAE 
EAE is a disease model with several similarities to MS. Various autoantigens can be used to 
induce EAE but in this thesis we have used only MOG. For EAE in rat, MOG is emulsified in 
incomplete Freund’s adjuvant and injected subcutaneously at the tail base. For EAE in 
mouse, MOG is emulsified in complete Freund’s adjuvant, i.e. it also includes heat killed 
mycobacteria, and is injected similarly, followed by an intraperitoneal injection of pertussis 
toxin, which is repeated on day 2. 
 
Skin inflammation models 
Oxazolone model: The small molecule oxazolone is an irritant that is often used to induce 
delayed type hypersensitivity (hypersensitivity type IV) in experimental animals, which is 
regarded as a model of atopic dermatitis. Mice are sensitized by applying oxazolone on 
shaved skin of the back. After 6 days, an immune reaction is elicited by applying oxazolone 
on one of the ears. The degree of inflammation is quantified by measuring the ear thickness 
24 hours later with a high precision caliper. 
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Imiquimod model: One of the more frequently used murine models of psoriasis is induced by 
daily applications of imiquimod cream on shaved skin274. The main readout is thickening of 
the epidermis, which is assessed on histological sections. Imiquimod is a small molecule that 
is used as a topical treatment of various skin conditions including cancerous and 
precancerous lesions. It is an immune modifier that acts by activating TLR7 on innate 
immune cells. 
 
In vivo cytokine treatment 
As a confirmatory experiment, recombinant rat IL-22 or PBS was injected subcutaneously 
and the effects were compared to those seen when knocking down Il22ra2.  
 
Real-time quantitative PCR 
Gene expression has been used extensively throughout the thesis to assess cellular responses 
in experimental settings. It is assumed that a change in mRNA quantities for a particular gene 
also will be reflected on the protein level. Comprehensive studies have shown a moderate 
correlation between mRNA and protein copy numbers when broadly assessing several tissues 
and cell lines with a median Pearson correlation coefficient of 0.6275. However if a gene-
specific factor is introduced the same value increases to 0.93. This means that mRNA levels 
reflect changes in protein levels well in qualitative terms, i.e. let us know if there is an 
increase or decrease in translation, but less well in quantitative terms275. Naturally, having 
data on protein levels is generally preferred. But protein quantification methods are often 
associated with significant obstacles and therefore need more extensive protocol 
optimization, for example regarding sample preparation or antibody staining, making them 
impractical in certain circumstances. In this thesis, real-time quantitative PCR has been used 
as a screening tool or when protein quantification has not been attainable or practical.  
 
Flow cytometry 
Although any cell can potentially be analyzed by flow cytometry, it requires that you can 
prepare a single cell suspension, which imposes a challenge when investigating most tissues. 
Immune cells are more or less migratory and therefore only have loose attachments to their 
surroundings. For this reason, lymphoid tissue can easily be disintegrated yielding free single 
cells. However, light treatment with enzymes may be needed to increase the yield of certain 
cells, such as APCs. Getting immune cells from other tissues generally requires more 
extensive mechanical and enzymatic manipulation, both of which compromise cell viability 
and cell surface marker integrity. In this thesis digestion of CNS, lymphoid and skin tissue 
has been used for analysis by flow cytometry. 
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Cell sorting 
Antibody based sorting of cells has been performed using the technologies fluorescence-
activated cell sorting (FACS) or the simplified magnetic-activated cell sorting (MACS). 
FACS makes use of a flow cytometer and allows for a large degree of control over the 
sorting. It is indispensable when complex gating is required to define the population of 
interest or to get accurate information regarding sorting purity. MACS uses magnetically 
labeled antibodies that can be separated using simple equipment. It allows for less control but 
is simple and can more easily be performed in sterile conditions, important if the cells are to 
be cultured afterwards. 
 
Isolation of peripheral blood mononuclear cells and in vitro stimulation 
Peripheral blood mononuclear cells were isolated from heparinized blood samples or buffy 
coats using Ficoll gradient centrifugation. CD14+ monocytes were isolated using MACS 
beads followed by differentiation in vitro using recombinant cytokines and other stimuli. 
 
ELISA 
Enzyme-linked immunosorbent assay (ELISA) has been used to determine the concentration 
of circulating antibodies or other proteins in serum, plasma, or CSF.  
 
Western blot 
In paper II, changes in mRNA expression of Il1b and Cxcl2 in skin biopsies were confirmed 
on the protein level using western blot. 
 
Histopathology and immunofluorescence  
To corroborate the difference in EAE severity in paper I, mouse spinal cord was stained with 
hematoxylin and eosin to assess inflammation and Luxol fast blue to assess demyelination. 
Immunofluorescence staining of mouse IL-22BP was performed on naïve lymph nodes. In 
paper II, hematoxylin and eosin staining was performed on skin biopsies from the two disease 
models. In paper III, immunocytochemistry was performed on cultured mouse 
oligodendrocytes to visualize cell surface expression of IL-22R. In paper IV, 
immunofluorescence staining was performed on draining lymph nodes from MOG-
immunized rats to visualize T cells, B cells, and germinal centers. 
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SNP genotyping 
In paper II, SNP-genotyping was performed using TaqMan SNP-genotyping assays.  
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4 RESULTS AND DISCUSSION 
 
The results of papers I-IV will be discussed in the following section. 
4.1 IL-22BP INCREASES SEVERITY OF MURINE NEUROINFLAMMATION 
Background: We had previously reported a quantitative trait locus (QTL) on rat chromosome 
1 with influence on EAE severity246. In that study, a congenic rat strain was created, to 
confirm the effect of the QTL, by breeding so that the chromosomal fragment of interest from 
the relatively EAE-resistant PVG strain was isolated on DA genetic background. This 
congenic strain has milder EAE compared to wild type DA rats, consistent with the linkage 
data. The congenic fragment includes several genes, of which Il22ra2 appeared as the most 
plausible gene responsible for the observed effect on EAE. This was based on lower Il22ra2-
expression in the protected congenic strain compared to wild type DA rats as well as reports 
of its involvement in innate immunity. Furthermore, we showed, in a Nordic cohort, that 
SNPs near IL22RA2 associate with MS risk. Shortly after, data from a large scale GWAS 
performed by the International MS Genetics Consortium (IMSGC) were made public 
showing that rs17066096, a SNP 14 kb downstream of IL22RA2 strongly associate with MS 
susceptibility44. The role of IL22RA2 in MS warranted further investigations and the next step 
was to definitely confirm the involvement of Il22ra2 in EAE. 
 
Hypothesis: Mice with a complete deletion of Il22ra2 have less severe EAE. 
 
Main results: Il22ra2-/- mice subjected to MOG-induced EAE had a slightly earlier onset of 
disease and a similar severity at peak of disease compared to littermate wild type controls. In 
contrast, after the peak of disease the knockout mice had a better recovery. We did not see 
any changes in the cellular composition of secondary lymphoid organs in untreated mice or 
significant effects on T cell phenotype in draining lymph nodes during priming, day 7. 
However, Il22ra2-/- mice had less demyelination and inflammation on spinal cord 
histopathology and assessment of CNS infiltrating cells by flow cytometry showed a 
significant decrease in Ly6C+ inflammatory monocytes. 
 36 
             
 
Figure 5. Il22ra2-/- mice had less severe clinical signs of EAE and less demyelination in the 
spinal cord compared to wild type mice. * denotes a p-value < 0.05 and ** is a p-value < 0.01 
using Mann-Whitney U test. 
 
IL22RA2 codes for the soluble protein IL-22BP, which acts as an IL-22 antagonist by binding 
tightly to it so that it cannot dock with the signaling membrane-bound IL-22R. When the 
work started for this paper Th17 cells had relatively recently been identified as an important 
pathogenic factor for EAE142,276,277. IL-17 and IL-22 are signature cytokines of Th17 cells, 
which had spurred a few investigations into the role of IL-22 in EAE and MS145,270. Most 
notably, one paper had shown that mice with a constitutive deletion of Il22 have no apparent 
EAE phenotype. The authors for that paper correctly concluded that IL-22 is not necessary 
for IL-22 induction but in the literature the message tended to be skewed towards IL-22 not 
having any role in EAE and initially that was also how I regarded those results. To try to 
reconcile these findings with the protective effect of IL-22BP-deletion we postulated the 
existence of an alternate ligand for IL-22BP and proceeded by trying to find evidence for this 
using immunoprecipitation. Recombinant mouse IL-22BP or antibodies for mouse IL-22BP 
were used as bait and lymph node tissue lysate or serum were added, using various 
immunoprecipitation reagents. The goal was to catch proteins that interacted specifically with 
IL-22BP or already formed IL-22BP-ligand complexes, which then could be eluted, 
visualized on a protein gel, and identified by mass spectrometry. These were exciting 
experiments to perform considering the potential implications of any positive results. 
However, after a few months without progress the research question was abandoned. 
Nevertheless, the experience gave me valuable insight into protein chemistry and some of the 
specific challenges inherent to methodologies in that field. 
 
WT 
Il22ra2-/- 
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Similarly, the question of what cell type(s) express IL-22BP was not easily answered. In a 
first screen of Il22ra2 mRNA expression in a panel of tissues in wild type mice we observed 
highest expression in lymphoid organs and we proceeded to define the cellular source. For 
soluble proteins, such as IL-22BP, antibody staining tends to be more challenging and if 
positive staining is achieved it may not clearly indicate which cell is the producer. 
Furthermore, no IL-22BP-antibody staining had been reported in the literature at this time. 
We therefore initially attempted to localize Il22ra2 expression in rat lymph node using in situ 
hybridization. Despite some promising initial results, a robust assay could not be established. 
Instead, we chose a different strategy and FACS-sorted cell populations from mouse lymph 
nodes based on expression of various combinations of cell surface markers. This way, 
Il22ra2 expression was localized to both the CD11b+ CD11c+ as well as the CD11b+ CD11c- 
populations, which can be broadly interpreted as myeloid cells. Although positive antibody 
staining of mouse IL-22BP in lymph node section was achieved later and included in the 
paper, co-staining for CD11b was not possible due to protocol incompatibilities. 
 
4.2 IL-22BP DECREASES SEVERITY OF MURINE SKIN INFLAMMATION 
 
Background: We had now shown that Il22ra2-/- mice have less severe disease in EAE, 
suggesting a protective role for IL-22278. In contrast, there is strong evidence for IL-22 having 
a disease-driving influence on psoriasis, through its direct effects on keratinocytes251,252. The 
role of IL-22BP in skin inflammation had not previously been investigated. Paradoxical 
effects of cytokines on different inflammatory diseases have been observed previously, most 
notably for TNF. TNF-neutralization is a very successful treatment for rheumatoid arthritis 
and inflammatory bowel disease but increases disease activity in MS75. 
 
Hypotheses: 1) Mice with a complete deletion of Il22ra2 will have increased severity of 
disease in experimental models of skin inflammation and 2) The MS-risk associated allele of 
rs17066096, which is located near IL22RA2, will have a protective influence on psoriasis.  
 
Main results: Il22ra2-/- mice had more severe disease in oxazolone-induced contact 
hypersensitivity. To investigate the generalizability of this observation we included also the 
psoriasis model imiquimod-induced psoriasiform inflammation. Similarly, the Il22ra2-/- mice 
had more severe disease, evidenced by increased epidermal thickness but also more 
infiltrating neutrophils, and higher expression of neutrophil attracting factors in the skin, such 
as IL-1β and CXCL2. In the oxazolone-model we did not see any difference in immune cell 
infiltration, suggesting that different pathways are involved in the two models. We performed 
a genetic association study but could not demonstrate an opposite influence of rs17066096 on 
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MS and psoriasis. However, a trend was observed suggestive of reduced severity of psoriasis 
in carriers of the MS risk allele.  
 
 
                            
 
Figure 6. Il22ra2-/- mice had more severe histopathological manifestations of imiquimod-
induced psoriasiform inflammation, assessed by measuring epidermal thickness. P-values 
were calculated using unpaired Student’s t test. Representative images of hematoxylin and 
eosin stained skin is shown. Scale bar is 100 μm. 
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Figure 7. Il22ra2-/- mice had more infiltration of neutrophils in the inflamed skin in the 
context of imiquimod-induced inflammation. Live CD45+ cells were separated into CD11b+ 
Ly6G- monocytes/macrophages, CD11b+ Ly6G+ neutrophils, CD3+ γδTCR- αβT cells, and 
CD3+ γδTCR- γδT cells. P-values were calculated using unpaired Student’s t test. 
 
Our study of the role of IL-22BP in skin inflammation started with a number of small 
experiments using the oxazolone-model. These experiments were primarily motivated as a 
form of control of our genetic model - if IL-22BP is successfully deleted in the Il22ra2-/- mice 
we expect to see increased severity of IL-22-driven pathology. Although there was little 
information on IL-22 in relation to contact hypersensitivity, we chose this model as it was 
easy to perform. The results clearly showed increased severity of disease in the Il22ra2-/- 
mice, as expected. Considering that the role of IL-22BP in regulating the pathological effects 
of IL-22 in any model of skin inflammation had not been addressed, we started collaboration 
with a skin inflammation research group to investigate this further. 
 
We could show that IL-22BP is an important regulator of inflammation in mouse models of 
psoriasis and atopic dermatitis. It was satisfying to see that the effect of IL-22BP on 
imiquimod-induced psoriasiform inflammation was later confirmed in a report published 
shortly after ours279,280. This is important information in relation to psoriasis and other 
inflammatory disorders of the skin, in which inhibition of IL-22 is discussed as therapy, 
suggesting another way of modulating the effects of this cytokine.  
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There are a limited number of cytokines that are known to have a dedicated antagonist 
molecule. One can speculate that evolutionary pressure has resulted in the use of IL-22BP as 
an important break in the IL-22-system, as too much will lead to pathology exemplified by 
psoriasis and to little will increase to risk of other pathologies exemplified by MS. It would 
not be surprising then if the expression of IL-22BP was genetically regulated, resulting in 
genotypes with opposite risk of psoriasis and MS. However, we could not provide strong 
evidence for this hypothesis but this does not exclude that such relationships exist. A larger 
cohort of psoriasis samples and more sub-phenotypes of both diseases may be necessary and 
possibly genotyping of other SNPs. 
 
                     
Table 2. Carriers of the MS-risk associated (minor) allele of rs17066096 were less frequent 
in psoriasis patients with severe disease in the studied sample but not to the degree that 
statistical inference could be made. Abbreviations: a/b, number of minor/major alleles; OR, 
odds ratio; CI, confidence interval. P-values were calculated using the Chi-square test.. 
 
4.3 IL-22BP LEVELS ARE ASSOCIATED WITH MS RISK 
 
Background: IL22RA2 is the candidate gene for an MS-risk locus defined by genetic marker 
rs1706609644,45. The gene product IL-22BP promotes disease severity in mouse EAE278. 
 
Hypotheses: 1) The disease predisposing G allele of rs17066096 will give higher expression 
of IL-22BP and 2) the protective effect of Il22ra2-deletion in mouse is dependent on IL-22. 
 
Main results: Although human circulating immune cells did not express IL22RA2 ex vivo, 
monocytes differentiated in vitro with IL-4 and GM-CSF did. This combination of cytokines 
is known to result in a DC-like phenotype. Interestingly, the expression of IL22RA2 was 
amplified even further by the addition of the retinoic acid receptor agonist AM580 
throughout the differentiation process. Using this in vitro expression system, we saw that 
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cells from healthy blood donors that carry the disease predisposing G allele of rs17066096 
had higher expression of IL22RA2. No significant differences were observed when 
performing the experiment on samples from MS patients, however. To link subtle changes in 
IL22RA2 expression to neuroinflammation we performed EAE in a rat strain that enables 
inducible knockdown of Il22ra2 through doxycycline controlled expression of a gene-
specific shRNA in vivo. Knockdown of Il22ra2 had a dose-dependent protective effect on 
EAE. Using mouse strains with deletion of Il22ra2, Il22, or both genes, we saw that the 
protective effect of Il22ra2-deletion was indeed lost in the absence of Il22. IL-22BP protein 
was present in rat and human CSF and levels correlated with disease course and number of 
MRI lesions, respectively. By sorting CNS cells from naïve mouse brains we saw that 
Il22ra2 was expressed by microglia. 
 
In this paper we addressed all stated aims of this thesis. First off, rs17066096 is located 14 kb 
downstream of IL22RA2 and is associated with MS risk - but does it influence IL22RA2 
expression? This is a key question in the thesis but two aspects in particular made it difficult 
to address: 1) IL22RA2 is not expressed in cells that are easily accessible for study and 2) the 
minor allele frequency of this SNP is relatively low (≈ 0.23) with only about 5 % in a 
randomly selected group of individuals being homozygous carriers. To circumvent this, we 
wanted to establish an in vitro assay to study IL22RA2 expression in peripheral blood cells. 
By searching the gene expression omnibus (GEO) DataSets, a searchable database that 
contains curated datasets from gene expression studies, we found that human monocytes 
differentiated with GM-CSF and IL-4 express IL22RA2 and that expression is amplified by 
including retinoic acid receptor agonist AM580. After some optimizations we chose this as 
our assay. Next step was to collect blood samples and freeze the cells to be able to run all 
samples in parallel. However, we needed to preselect individuals based on rs17066096 
genotype to have sufficient numbers of homozygous carriers of the risk allele. This could 
fortunately be arranged because many MS patients that regularly come to the neurology clinic 
have contributed samples for genomic studies and therefore already have been genotyped for 
rs17066096. Recruitment was done by research nurses and the collection of blood samples 
from 10 homozygous individuals took more than 6 months. Similar logistics were needed to 
collect samples from healthy individuals but this time collaboration was set up with the 
neighboring city Uppsala. An infrastructure was in place there in which individuals who were 
regular blood donors also had been densely genotyped, including rs17066096. Whenever an 
individual with the right genotype came to donate blood, a buffy coat was sent to our lab. 
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Figure 8. Monocytes from healthy blood donors carrying MS-risk allele rs17066096G 
expressed more IL22RA2 after in vitro differentiation with GM-CSF, IL-4, and AM580. P-
values were calculated using unpaired Student’s t test. 
 
We next resolved the question that arose in the beginning of the project - is the protective 
effect of knocking out Il22ra2 in EAE mediated by IL-22? The available literature on IL-22 
offered very little that could explain the disease course seen in the Il22ra2-/- mice in paper I, 
which had spurred our attempts to find other ligands for IL-22BP. But by also deleting Il22 
we could see that the protective effect of Il22ra2 deletion was lost.  
 
                  
 
Figure 9. The protective effect of Il22ra2-deletion was lost in the absence of Il22. 
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Some inconsistencies are apparent when comparing the EAE disease course in the rat and 
mouse experiments in this paper as well as in previous papers. In paper I, the Il22ra2-/- mice 
had a slightly earlier onset that was statistically significant. At peak of disease the two groups 
are equal but right after that, the knockout mice clearly have a better recovery. This disease 
course was consistently seen, and although only data from male mice are reported in the 
paper, the same pattern was seen in experiments using females. Two plausible explanations 
for the earlier onset are 1) IL-22 is often regarded as a pro-inflammatory cytokine and could 
therefore boost or accelerate immune cell priming and 2) IL-22 has been suggested to open 
the blood brain barrier in the setting of a human in vitro model, which could explain the 
earlier onset of paralysis. The question of the blood brain barrier was intriguing but the 
observed effect was deemed to be too small to be feasible to investigate further. We wanted 
to address the issue of immune cell priming by adoptive transfer EAE but had at that time 
difficulties setting up the model in the lab. However, in paper III the EAE disease course in 
the Il22ra2-/- mice looks different. The onset is the same as wild type mice and the protective 
effect is apparent earlier, so that also the peak of disease is distinctly lower. The explanation 
for this difference is elusive but may involve subtle differences in several parameters such as: 
interbreeding with two other mouse strains with slightly different C57BL/6 background, an 
effect of the cre-enzyme, breeding has moved to a different room in the animal facility, or 
different MOG batch. Interestingly, the EAE disease course in these experiments is more 
similar to that seen in rats. Using the knockdown rat we see a dose-dependent effect on EAE 
severity and susceptibility, where 20 mg/l of doxycycline administered before immunization 
gives a disease course similar to the knockout mice and higher doses make the transgenic rats 
completely resistant. The reason for this dramatic effect in rats that likely still has some IL-
22BP production intact when complete knockout in mouse gives a milder phenotype is 
intriguing. Several plausible explanations can be suggested for this but perhaps most 
importantly that constitutive knockout animals develop without the targeted gene from the 
gamete stage to adulthood and have during that time the possibility to compensate for the lost 
function in ways that are difficult to predict. Other plausible explanations include the use of a 
different species and a different immunization protocol. It is interesting to compare these 
experiments with those in the previous publication using the congenic strain, Dc1P. This is 
the rat strain that included a large number of genes from the protected PVG on DA 
background, which had lower Il22ra2 expression and relatively mild EAE246. Compared to 
DA controls, disease course in Dc1P is characterized by a similar onset and then a trend for a 
lower severity during the peak of disease but significant difference only at the chronic stage 
of EAE, i.e. somewhat in between what we see in all the later experiments in mouse and rat. 
 
4.4 IL-22BP FACILITATES IMMUNE CELL PRIMING 
 
Background: IL-22 is implicated in the pathogenesis of several inflammatory diseases but its 
effect on B and T cell activation and phenotype is little studied. 
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Hypothesis: IL-22 influences the priming phase of an adaptive immune response. 
 
Main results: Il22ra2 was highly expressed in naïve lymph node tissue. Upon immunization 
of rats with MOG in incomplete Freund’s adjuvant, expression of Il22ra2 decreased reaching 
nadir at day 7, which coincided with a peak in Il22 expression. In the late stage of EAE, 
Il22ra2 expression in spleen correlated with transcripts related to B cell function, suggesting 
that common pathways are involved.  
 
 
 
Figure 10. Using the Ingenuity Pathway Analysis (IPA) software, Il22ra2 expression in rat 
splenic tissue from day 35 of EAE correlated with B cell related transcripts. P-values were 
calculated using Fisher’s exact test with Benjamini-Hochberg correction for multiple testing. 
 
Using the inducible Il22ra2-knockdown rat strain from paper III, we showed that reduced 
Il22ra2 expression during immune cell priming resulted in smaller lymph nodes with a 
proportional reduction in B cell numbers. Expression of B cell-attracting Cxcl13 and several 
other chemokines were reduced in naïve lymph nodes in rats after knockdown of Il22ra2 
expression. Injection of recombinant rat IL-22 subcutaneously during priming also reduced 
expression of lymph node Cxcl13 in the draining lymph nodes. Both B and T cell effector 
functions were affected by reduced expression of Il22ra2 during immune cell priming. There 
was a trend suggestive of less expression of activation markers CD80 and CD86 in lymph 
node B cells, and less MOG specific IgG2b in serum, both from day 7 after immunization. At 
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the same time point, we observed less IFNγ+ T cells and more Foxp+ regulatory T cells after 
in vitro restimulation of lymph node cells with MOG. 
 
                                       
 
Figure 11. Knocking down Il22ra2 expression before immunization with MOG lead to a 
reduction in Cxcl13 expression day 7 after immunization. A similar effect was seen when 
recombinant rat IL-22 was injected subcutaneously at immunization and again day 4. P-
values were calculated using one-way ANOVA and Tukey’s post hoc test. 
 
 
    
 
Figure 12. Serum anti-MOG antibodies day 7 after immunization showed a reduction 
specifically in IgG2b when Il22ra2 expression was knocked down prior to immunization. P-
values were calculated using unpaired Student’s t test. 
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Figure 13. Lymph node T cells taken day 7 after immunization and restimulated with MOG 
in vitro expressed less IFNγ when Il22ra2 expression has been knocked down prior to 
immunization. P-values were calculated using unpaired Student’s t test.                            
 
One of the first things that struck us when starting our investigations of IL-22BP is that when 
comparing the tissue distribution in naïve rats and mice, Il22ra2 expression is highest in 
lymph nodes, where we detect very little transcripts for Il22 or IL-22R subunit Il22ra1. Upon 
immunization with MOG expression of Il22ra2 decreases, which is mirrored by an increase 
in Il22 expression. It seems that an intricate system is in play allowing for IL-22 signaling to 
occur during immune cell priming, which is controlled by IL-22BP. There was no literature 
available on IL-22 mediated effects in secondary lymphoid organs so to explore this we used 
a dataset produced earlier in the lab consisting of gene array results from spleen samples 
harvested from late stage EAE from 150 rats. Surprisingly, we found that the expression of 
Il22ra2 in these samples correlated very distinctly with expression of B cell related genes. 
This seemed unrelated to the data we were getting using the knockout mouse as no striking 
differences had been seen in B cell numbers or serum antibody concentrations. Consequently, 
we decided to elaborate on this finding in a separate publication addressing the role of IL-
22BP in the priming phase of an adaptive immune response. 
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5 CONCLUDING REMARKS 
 
In this thesis, the roles of IL-22 in several inflammatory disease models have been addressed, 
for the most part indirectly by manipulating the endogenous antagonist molecule IL-22BP. 
The work was primarily motivated by MS-associated genomic variation close to its gene, 
IL22RA2. We have accumulated evidence that consistently suggest a disease-driving role for 
IL-22BP in autoimmune neuroinflammation, in three species:  
- a congenic rat strain with a natural variant of Il22ra2, which results in lower 
expression of the gene, has less severe EAE (not included in this thesis), 
- a transgenic mouse strain with a specific deletion of Il22ra2 has less severe EAE, 
- a transgenic rat strain with induced knockdown of Il22ra2 has less severe EAE 
- the protective allele of MS-associated SNP rs17066096 is associated with lower 
expression of IL22RA2, under specific circumstances in vitro. 
We also show in mice that the effect is dependent on the presence of IL-22, suggesting a 
protective role for this cytokine in EAE and possibly also MS. 
This is contrasted with psoriasis, where IL-22 directly promotes the cardinal manifestations 
of the disease. We confirm this in a mouse model of psoriasis and show that IL-22BP is an 
important regulator of skin inflammation. We could not link rs17066096 genotype to 
psoriasis susceptibility or severity, however. 
We show that IL-22BP is present in the CSF of rats and humans and that the transcript is 
expressed in microglia in mice. Suggesting a possible role in the CNS in the case of MS. An 
alternative explanation, although not mutually exclusive, is the broad dampening effect on 
adaptive immune activation in peripheral lymph nodes that we have characterized in rat. We 
have recently detected IL22RA1 expression on a subset of human T cells ex vivo and are 
currently investigating this further as a possible mechanism for the results reported in relation 
to EAE and MS. We find it plausible that IL-22 may act directly on T cells to diminish their 
encephalitogenic potential.  
 
Relatively simple experiments that could have been done for this thesis but were not due to 
time constraints include: 
- conditional knockout of Il22ra2 using cre-lines specific for immune cells, myeloid 
cells, and microglia to locate the cellular source responsible for the effect seen in 
EAE, 
- and conditional knockout of Il22ra1 using the Vav1-cre strain, to test the wide-spread 
notion that IL-22 generally does no act directly on immune cells, as well as other cre-
strains to narrow down the responding cell responsible for the effect of IL-22 seen in 
EAE. 
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We have established IL-22BP as a pathogenic factor in autoimmune neuroinflammation in rat 
and mouse, making it a potential therapeutic target for MS that warrants further investigation. 
Important outstanding questions include: 
- What pathway or mechanism is involved in the protective effect of IL-22 on EAE. 
- What would be the most appropriate strategy to achieve this effect pharmacologically, 
neutralizing IL-22BP antibody? IL-22 receptor agonist? Other targets downstream of 
the IL-22 receptor? 
Another major question is: what are the downstream signaling effects of the different alleles 
of rs17066096? Also, rs17066096 may not be the causative SNP, but in strong LD with it. 
One can argue that, as the effects of IL-22BP are unraveled and more evidence is gathered 
regarding its role in MS and EAE, the importance of getting to the bottom of this question 
may lessen. However, as a basic science question it is tremendously important. Based on the 
data available today from the very ambitious project encyclopedia of DNA elements 
(ENCODE), rs17066096 does not appear to lie in close proximity to any known regulatory 
elements281. Understanding how rs17066096, or a linked SNP, influences the risk of getting 
MS could elucidate general mechanisms of value for investigations into the genetic risk 
factors of any disease. 
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